# Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects

> **NCT02183636** · PHASE1 · COMPLETED · sponsor: **Boehringer Ingelheim** · enrollment: 39 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Linagliptin/pioglitazone, FDC formulation C5
- **DRUG:** Linagliptin/pioglitazone, FDC formulation C8
- **DRUG:** Linagliptin tablet
- **DRUG:** pioglitazone tablet (Actos®)

## Key facts

- **NCT ID:** NCT02183636
- **Lead sponsor:** Boehringer Ingelheim
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-08
- **Primary completion:** 2009-12
- **Final completion:** —
- **Target enrollment:** 39 (ACTUAL)
- **Last updated:** 2014-07-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02183636

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02183636, "Relative Bioavailability of Two Fixed Dose Combination Tablets of Linagliptin/Pioglitazone Compared With Single Linagliptin and Pioglitazone Tablets Administered Together to Healthy Male and Female Subjects". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02183636. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*